Amylin Pharmaceuticals, LLC Patent applications |
Patent application number | Title | Published |
20160120950 | Pharmaceutical Formulations Comprising Incretin Mimetic Peptide and Aprotic Polar Solvent - The present disclosure is directed to stable pharmaceutical formulations and uses thereof. | 05-05-2016 |
20150258177 | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA - The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1 (7-37), GLP-1 (7-37) analogs (e.g., GLP-1 (7-36)-NH | 09-17-2015 |
20150238568 | EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES - Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide. | 08-27-2015 |
20150231204 | PANCREATIC POLYPEPTIDE FAMILY MOTIFS, POLYPEPTIDES AND METHODS COMPRISING THE SAME - The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use. | 08-20-2015 |
20150174209 | INSULIN-PRAMLINTIDE COMPOSITIONS AND METHODS FOR MAKING AND USING THEM - In alternative embodiments, the invention provides formulations, pharmaceutical compositions, devices and other products of manufacture comprising a therapeutically effective mixture of an insulin and a pramlintide, and methods for making and using them. For example, methods and compositions of the invention are used in the treatment or amelioration of a diabetes, a dementia or Alzheimer's disease, any abnormality of blood glucose control, an inability to control blood glucose, an elevation of fasting glucose or Impaired Fasting Glucose (IFG), an abnormality of tolerance to a glucose load or Impaired Glucose Tolerance (IGT), a hyperglycemia induced by an illness, a trauma, a medication administration or a form of metabolic, psychological or physical stress, or a hyperglycemia induced by steroids (steroid-induced diabetes), a latent autoimmune diabetes in adults (LADA), a postprandial or reactive Hypoglycemia or an insulin resistance, a PolyCystic Ovary Syndrome (PCOS), a ketoacidosis, a gestational diabetes, a hyperkalemia, a cancer or cachexia, a beta blocker overdose, or a jaundice. In alternative embodiments, the invention provides insulin pumps, devices, subcutaneous insulin infusion therapy devices, continuous subcutaneous insulin infusion therapy devices, infusion therapy devices, reservoirs, ampoules, vials, syringes, cartridges, disposable pen or jet injectors, prefilled pens or syringes or cartridges, cartridge or disposable pen or jet injectors, two chambered or multi-chambered pumps, syringes, cartridges or pens or jet injectors, or an artificial pancreas, comprising a formulation having an insulin:pramlintide ratio of the invention. | 06-25-2015 |
20150157725 | TRANSMUCOSAL DELIVERY OF PEPTIDES AND PROTEINS - Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid, at least one additional absorption enhancing agent, and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions. | 06-11-2015 |
20150152158 | METHODS TO RESTORE GLYCEMIC CONTROL - Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce β cell regeneration. | 06-04-2015 |
20150150948 | METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT - Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA | 06-04-2015 |
20150111824 | Pharmaceutical Formulations Comprising Incretin Mimetic Peptide and Aprotic Polar Solvent - The present disclosure is directed to stable pharmaceutical formulations and uses thereof. | 04-23-2015 |
20150111246 | SITE-SPECIFIC ENZYMATIC MODIFICATION OF EXENDINS AND ANALOGS THEREOF - There is provided inter alia a method of covalently attaching an amine derivatizing agent to a glutamine of a first polypeptide. The method includes adding an amine derivatizing agent, a transglutaminase a first polypeptide which includes a glutamine, and a co-solvent to a reaction mixture. The method further includes allowing the amine derivatizing agent to react with the glutamine of the first polypeptide in the reaction mixture to form an amide bond, thereby covalently attaching the amine derivatizing agent to the glutamine of the first polypeptide. | 04-23-2015 |
20150080308 | Formulations and Uses of Exendins and Exendin Agonist Analogs - Provided herein are formulations containing exendins, exendin agonists and/or exendin analogs and methods of using the exendins, exendin agonists and/or exendin analogs and formulations thereof to treat glucagonoma and necrolytic migratory erythema, or to suppress glucagon secretion. | 03-19-2015 |
20150080307 | EXENDINS AND EXENDIN AGONIST ANALOGS TO REGULATE GASTROINTESTINAL MOTILITY - Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents. | 03-19-2015 |
20150056285 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS - The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance. | 02-26-2015 |
20140371148 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME - Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders. | 12-18-2014 |
20140256621 | ENGINEERED POYPEPTIDES HAVING ENHANCED DURATION OF ACTION AND REDUCED IMMUNOGENICITY - Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease. | 09-11-2014 |
20140249299 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 09-04-2014 |
20140249077 | GEL COMPOSITIONS - The present invention is directed to compositions and methods of preparation of phospholipid gels. | 09-04-2014 |
20140249076 | AMYLIN-CALCITONIN CHIMERIC PEPTIDES CONJUGATED TO DURATION ENHANCING MOIETIES - Provided herein are amylin-calcitonin peptide conjugates having enhanced duration of biological activity, and methods of use thereof. The amylin-calcitonin peptide conjugates include duration enhancing moieties, such as water soluble polymers and long chain aliphatic groups, bound to the amylin-calcitonin peptide. Methods of use are provided for treatment of an eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyperlipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis or osteoarthritis. | 09-04-2014 |
20140235535 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION WITH REDUCED IMMUNOGENICITY - Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease. | 08-21-2014 |
20140221287 | Amylin Peptides and Derivatives and Uses Thereof - There are provided polypeptide conjugates having enhanced duration of biological activity, and methods of use thereof. The polypeptide conjugates include duration enhancing moieties, including water soluble polymers, bound to the polypeptide components of defined sequence. Methods of use are provided for treatment of metabolic disorders. Methods of use are provided for treatment of an eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyper lipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis, osteoarthritis, or short bowel syndrome. | 08-07-2014 |
20140221282 | LONG DURATION DUAL HORMONE CONJUGATES - There are provided compounds having two peptide hormones bound to a central water-soluble polymeric spacer and methods of use thereof. | 08-07-2014 |
20140220134 | METHOD FOR TREATING DIABETES WITH EXTENDED RELEASE FORMULATION OF GLP-1 RECEPTOR AGONISTS - The disclosure provides methods for treating diabetes, treating overweight, treating obesity, reducing body weight, treating cardiovascular diseases, treating fatty liver diseases, treating gastrointestinal diseases, and treating neurodegenerative diseases through the once monthly administration of pharmaceutical formulations containing a non-aqueous carrier and GLP-1 receptor agonists that provides therapeutically effective plasma concentration levels of the GLP-1 receptor agonists over the course of a month. | 08-07-2014 |
20140206613 | METHODS TO RESTORE GLYCEMIC CONTROL - Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce β cell regeneration. | 07-24-2014 |
20140200183 | TREATMENT OF CARDIAC ARRHYTHMIAS - Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment. | 07-17-2014 |
20140162943 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS - The disclosure provides N-terminus conformationally constrained compounds, which may comprise peptide mimetics and/or amino acid substitutions, which may be used in peptides, such as GLP-1 receptor agonist compounds, to induce β-turn secondary structure at the N-terminus. The N-terminus conformationally constrained compounds may be used for research purposes; to produce GLP-1 receptor agonist compounds having improved GLP-1 receptor binding activity, enzymatic stability, or in vivo glucose lowering activity; and to develop GLP-1 receptor agonist compounds which have fewer amino acid residues. The disclosure also provides GLP-1 receptor agonist compounds, such as exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs, comprising the N-terminus conformationally constrained compounds. The compounds are useful for treating various diseases, such as diabetes and obesity. The disclosure also provides methods for chemically synthesizing the N-terminus conformationally constrained compounds. | 06-12-2014 |
20140135261 | PEPTIDE YY AND PEPTIDE YY AGONISTS FOR TREATMENT OF METABOLIC DISORDERS - Methods and compositions are disclosed to treat metabolic disorders such as obesity, diabetes, and increased cardiovascular risk comprising administering a therapeutically effective amount of a PYY or a PYY agonist. | 05-15-2014 |
20140107019 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION - Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system. | 04-17-2014 |
20140066370 | Polypeptide Conjugate - The disclosure provides Polypeptide Conjugates with multiple improved pharmacological and pharmacokinetic properties and their use in treating various diseases and conditions, such as diabetes and/or obesity. | 03-06-2014 |
20140066368 | Methods For Affecting Body Composition - Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased. | 03-06-2014 |
20140056924 | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA - The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs (e.g., GLP-1(7-36)-NH | 02-27-2014 |
20140038891 | MODIFIED EXENDINS AND EXENDIN AGONISTS - Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake. | 02-06-2014 |
20130331322 | EXENDINS AND EXENDIN AGONIST ANALOGS TO REGULATE GASTROINTESTINAL MOTILITY - Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents. | 12-12-2013 |
20130296225 | Microcrystalline Y Receptor Agonists - The disclosure provides microcrystals of Y receptor agonists; microcrystalline pellets of Y receptor agonists, and microcrystalline suspensions of Y receptor agonists. Pharmaceutical compositions containing these microcrystals, microcrystalline pellets, and microcrystalline suspensions have prolonged pharmacokinetic profiles making them useful for once daily or once weekly administration. | 11-07-2013 |
20130225485 | Compositions and Methods for the Control, Prevention and Treatment of Obesity and Eating Disorders - Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the administration of an Amylin or an Amylin agonist to a subject in order to prevent, treat or control conditions or disorders associated with obesity, diet and nutrition. | 08-29-2013 |
20130209586 | Prevention And Treatment Of Cardiac Arrhythmias - Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment. | 08-15-2013 |
20130203661 | HIGHLY SOLUBLE LEPTINS - The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease. | 08-08-2013 |
20130196913 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 08-01-2013 |
20130184213 | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders - Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders. | 07-18-2013 |
20130184203 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS - The disclosure provides GLP-1 receptor agonist compounds having stabilized regions corresponding to alpha-helical regions of the natural peptide compounds. The disclosure also provides benzamide-containing exendin-4 analogs and alkene-constrained exendin-4 analogs, both of which have stabilized regions corresponding to alpha-helical regions of exendin-4. | 07-18-2013 |
20130172250 | Exendins To Lower Cholesterol And Triglycerides - Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microshperes encapsulating the exenatide. | 07-04-2013 |
20130172243 | Methods for Treating Diabetes and Reducing Body Weight - Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA | 07-04-2013 |
20130165379 | Formulations of Exendins and Exendin Agonist Analogs - Provided herein are formulations containing exendins, exendin, agonists and/or exendin analogs and methods of using the exendins, exendin agonists and/or exendin analogs and formulations thereof to treat glucagonoma and necrolytic migratory erythema, or to suppress glucagon secretion. | 06-27-2013 |
20130137631 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 05-30-2013 |
20130130977 | POLYMER-BASED SUSTAINED RELEASE DEVICE - This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. | 05-23-2013 |
20130089878 | GLP-1 RECEPTOR AGONIST BIOASSAY - Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLPI receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays. | 04-11-2013 |
20130035294 | Neuromedin and FN-38 Peptides for Psychotic Diseases - Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an NMX peptide, an FNX peptide, or an NMX receptor agonist, or analogs or derivatives thereof, to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders. | 02-07-2013 |
20130023471 | METHODS TO RESTORE GLYCEMIC CONTROL - Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce cell regeneration. | 01-24-2013 |
20130023470 | EXENDIN AND EXENDIN AGONISTS FOR EATING DISORDERS - Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 01-24-2013 |
20130023466 | Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders - Methods and compositions are disclosed to treat metabolic disorders such as obesity, diabetes, and increased cardiovascular risk comprising administering a therapeutically effective amount of a PYY or a PYY agonist. | 01-24-2013 |